[go: up one dir, main page]

CO6150124A2 - Composiciones de fenofibrato que contienen nanoparticulas de fenofibrato y metodos para hacerla - Google Patents

Composiciones de fenofibrato que contienen nanoparticulas de fenofibrato y metodos para hacerla

Info

Publication number
CO6150124A2
CO6150124A2 CO09000700A CO09000700A CO6150124A2 CO 6150124 A2 CO6150124 A2 CO 6150124A2 CO 09000700 A CO09000700 A CO 09000700A CO 09000700 A CO09000700 A CO 09000700A CO 6150124 A2 CO6150124 A2 CO 6150124A2
Authority
CO
Colombia
Prior art keywords
active agent
nanoparticles
agent composition
composition
less
Prior art date
Application number
CO09000700A
Other languages
English (en)
Inventor
Kristin Arnold
Hengsheng Heng
Kurt R Nielsen
Original Assignee
Mutual Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutual Pharmaceutical Co filed Critical Mutual Pharmaceutical Co
Publication of CO6150124A2 publication Critical patent/CO6150124A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Una composición de agente activo que comprende nanopartículas de agente activo que tienen un tamaño de partícula promedio efectivo de menos de 2000 nm, y un secuestrante particulado, en donde la composición no comprende surfactantes o fosfolípidos, y en donde el agente activo tiene una solubilidad en agua de menos de 1 mg/ml. 2.- La composición de agente activo de la reivindicación 1, en donde la composición se encuentra en la forma de una suspensión. 3.- La composición de agente activo de la reivindicación 2, en donde el tamaño de partícula promedio efectivo de las nanopartículas en la suspensión cambia por no más de 35% dentro de 2 semanas de una primera medición de tamaño de partícula.4.- La composición de agente activo de la reivindicación 1, en donde las nanopartículas de agente activo y el secuestrante particulado están dispuestos en una partícula de núcleo inerte para formar un granulado de agente activo. 5.- La composición de agente activo de la reivindicación 1, en donde las nanopartículas de agente activo tienen un de menos de 1500 nm.6.- La composición de agente activo de la reivindicación 1, en donde las nanopartículas de agente activo tienen un D90 de menos de 1000 nm.7.- La composición de agente activo de la reivindicación 1, en donde las nanopartículas de agente activo tienen un D90 de menos de 500 nm.8.- La composición de agente activo de la reivindicación 1, en donde el agente activo comprende fenofibrato, sirolimus, talidomida, o tacrolimus.9.- La composición de agente activo de la reivindicación 1, en donde el secuestrante particulado comprende un copolímero sensible a pH que tiene unidades de (met)acrilato hidrófobas y unidades de (met)acrilato solubles en ácido.10.- La composición de agente activo de la reivindicación 1, en donde el secuestrante particulado comprende copolímero butil metacrilato-(2-dimetilaminoetil) metacrilato-metil metacrilato.
CO09000700A 2006-06-26 2009-01-06 Composiciones de fenofibrato que contienen nanoparticulas de fenofibrato y metodos para hacerla CO6150124A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80582306P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
CO6150124A2 true CO6150124A2 (es) 2010-04-20

Family

ID=38704788

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09000700A CO6150124A2 (es) 2006-06-26 2009-01-06 Composiciones de fenofibrato que contienen nanoparticulas de fenofibrato y metodos para hacerla

Country Status (14)

Country Link
US (2) US20080050450A1 (es)
EP (1) EP2037888A2 (es)
JP (1) JP2009541485A (es)
KR (1) KR20090045205A (es)
CN (1) CN101505733A (es)
AU (1) AU2007265452A1 (es)
BR (1) BRPI0713533A2 (es)
CA (1) CA2656277A1 (es)
CO (1) CO6150124A2 (es)
IL (1) IL196108A0 (es)
MX (1) MX2009000035A (es)
NO (1) NO20090068L (es)
RU (1) RU2009102262A (es)
WO (1) WO2008002568A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100266B2 (en) 2006-01-12 2018-10-16 The Board Of Trustees Of The University Of Arkansas Dielectric nanolubricant compositions
CN101379168A (zh) 2006-01-12 2009-03-04 阿肯色大学评议会 纳米颗粒组合物、其制备方法及用途
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
CN101563170A (zh) 2006-10-19 2009-10-21 纳米技术有限公司 用超声波喷雾沉积法制作涂层的方法及装置
CN101553359B (zh) 2006-10-19 2014-04-16 阿肯色大学董事会 用静电喷涂法制作涂层的方法及装置
WO2009142852A2 (en) 2008-05-22 2009-11-26 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
EP2309978B1 (en) 2008-06-26 2018-12-26 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
WO2010002613A2 (en) 2008-07-02 2010-01-07 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US20100166857A1 (en) * 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
AU2010239689A1 (en) * 2009-04-21 2011-11-03 Selecta Biosciences, Inc. Immunonanotherapeutics providing a Th1-biased response
PT2575876T (pt) 2010-05-26 2018-03-26 Selecta Biosciences Inc Vacinas de nanotransportadores sintéticos multivalentes
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
WO2012041488A1 (en) * 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP5824688B2 (ja) * 2011-05-24 2015-11-25 センカ株式会社 ｐＨ応答性高分子微粒子及びその分散体の製造方法
WO2013192566A1 (en) * 2012-06-21 2013-12-27 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
US8476206B1 (en) 2012-07-02 2013-07-02 Ajay P. Malshe Nanoparticle macro-compositions
US8486870B1 (en) 2012-07-02 2013-07-16 Ajay P. Malshe Textured surfaces to enhance nano-lubrication
ES2745759T3 (es) 2012-11-12 2020-03-03 New Jersey Inst Technology Polvo compuesto farmacéutico de núcleo y cubierta y procedimientos de fabricación del mismo
MX2017000141A (es) * 2014-07-03 2017-04-25 Pfizer Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
EP3668484B1 (en) * 2017-08-17 2022-07-13 F. Hoffmann-La Roche AG Novel pharmaceutical compositions for basic or neutral, low molecular weight compounds
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
US12031128B2 (en) 2021-04-07 2024-07-09 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2586597A (en) * 1948-06-17 1952-02-19 Bell Telephone Labor Inc Oscillation generator
US2841138A (en) * 1957-03-11 1958-07-01 Ernest S V Laub Allergy testing device
US4058552A (en) * 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4228156C1 (de) * 1992-08-25 1993-10-21 Daimler Benz Ag Kraftstoffilteranordnung für eine Brennkraftmaschine
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
FR2721510B1 (fr) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
FR2742357B1 (fr) * 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6153525A (en) * 1997-03-13 2000-11-28 Alliedsignal Inc. Methods for chemical mechanical polish of organic polymer dielectric films
US6726934B1 (en) * 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
WO1999065469A2 (en) * 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
EE05190B1 (et) * 1998-11-20 2009-08-17 Rtp Pharma Inc. Dispergeeruvad fosfolipiididega stabiliseeritud mikroosakesed
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
US6482439B2 (en) * 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1302201A4 (en) * 2000-07-17 2007-09-05 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH IMPROVED ABSORBABILITY
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
AU2003235686A1 (en) * 2002-01-14 2003-07-30 Dow Global Technologies Inc. Drug nanoparticles from template emulsions
EP1517676A1 (en) * 2002-05-03 2005-03-30 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
AU2003304108B2 (en) * 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
AR041745A1 (es) * 2002-10-31 2005-05-26 Alza Corp Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos
FR2855756B1 (fr) * 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006060817A1 (en) * 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
WO2007070082A1 (en) * 2005-05-10 2007-06-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising teprenone
US8231907B2 (en) * 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use

Also Published As

Publication number Publication date
NO20090068L (no) 2009-03-23
WO2008002568A3 (en) 2008-04-17
IL196108A0 (en) 2009-09-01
CA2656277A1 (en) 2008-01-03
BRPI0713533A2 (pt) 2012-04-17
MX2009000035A (es) 2009-05-28
AU2007265452A1 (en) 2008-01-03
JP2009541485A (ja) 2009-11-26
CN101505733A (zh) 2009-08-12
KR20090045205A (ko) 2009-05-07
AU2007265452A2 (en) 2009-04-23
US20080050450A1 (en) 2008-02-28
EP2037888A2 (en) 2009-03-25
RU2009102262A (ru) 2010-08-10
WO2008002568A2 (en) 2008-01-03
US20080220076A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
CO6150124A2 (es) Composiciones de fenofibrato que contienen nanoparticulas de fenofibrato y metodos para hacerla
ES2526092T3 (es) Formulaciones de olanzapina en nanopartículas inyectables
ATE487470T1 (de) Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
ATE531368T1 (de) Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
CO5690538A2 (es) Formulaciones de multiples particulas de pantoprazol
AR063940A1 (es) Formulaciones de posaconazol nanoparticulado
JP2007512924A5 (es)
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
UY28744A1 (es) Particulados
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
CY1107649T1 (el) Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
JP2008538751A5 (es)
EP1781257A4 (en) PHARMACEUTICAL FORMULATIONS WITH MICROPARTICLES OR NANOPARTICLES OF AN AGENT
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
RU2007137846A (ru) Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
BR112012004967B8 (pt) forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis, seu uso e seu método de produção
BRPI0518772A2 (pt) formulaÇÕes de benzotiofeno em nanopartÍcula
PE20071003A1 (es) Formulacion de suspension de fexofenadina
AR029456A1 (es) Forma triturada
JP2006512286A5 (es)
DK1922061T3 (da) Oral, fast farmaceutisk formulering af tribulininhibitoren Indibulin
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
DE602004006899D1 (de) Kosmetische Zusammensetzungen enthaltend ein Copolymer aus Methacrylsäure, Cyclodextrin und ein Tensid sowie deren Verwendungen
AR055110A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo para ingredientes activos que tienen una solubilidad que depende en gran medida del ph